top of page



Logga C4C.png

Cell4Cure aquires technology platform from Idogen for creating therapies built on antigen specific tolerance 

Solna, Sweden, 1 September 2023, Cell4Cure AB - A Swedish private ATMP company working with antigen-specific dendritic cell mediated tolerance, aiming for curing disease where the immune system has become the enemy. Cell4Cure today announced that they we have won the formal bidding process to acquire the technology platform from Idogen AB. 

Cell4Cure AB is founded by a consortium of former board members of Idogen together with Barnik Invest AB. Cell4Cure will begin the planning and financing process during Q2 2024 to be able to re-start the clinical trial Toler8, aimed to recreate tolerance for FVIII treatment in Hemophilia A. The Phase I/II clinical study will primarily focus on safety and signs of tolerance induement.


For more information, please contact;

Christina Herder, CEO

Telephone: +46 703747156



About Cell4Cure

Cell4Cure AB is a Swedish, privately held cell therapy company committed to the development of treatments for inducing of immune tolerance. The company’s proprietary technology platform is based on dendritic cells mediating antigen-specific tolerance for the prevention or cure of diseases where the immune system is the enemy.

The company’s first clinical study, Toler8, is focusing on inducing tolerance to FVIII thereby preventing the occurrence of FVIII inhibitors, i.e. neutralizing antibodies, in hemophilia A patients.

Cell4Cure will as a first step deliver value to patients and shareholders by advancing this program to clinical proof of concept.

For more information visit

bottom of page